Hoth Therapeutics, Inc. (HOTH)

US — Healthcare Sector

Peers: ATXI REVB NRBO VRAX ZURA PHIO SONN ATNF CDIO BXRX TCON ADTX QNRX ALLR KRBP BDRX BWV HILS KPRX

Automate Your Wheel Strategy on HOTH

With Tiblio's Option Bot, you can configure your own wheel strategy including HOTH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol HOTH
Rev/Share 0.0
Book/Share 0.9067
PB 1.3511
Debt/Equity 0.0025
CurrentRatio 15.079
ROIC -0.833

MktCap 16180903.0
FreeCF/Share -0.6319
PFCF -2.012
PE -1.6202
Debt/Assets 0.0023
DivYield 0
ROE -1.0919

Rating B-
Score 3
Recommendation Neutral
P/E Score 1
DCF Score 4
P/B Score 4
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

HOTH
Published: June 24, 2025 by: PRNewsWire
Sentiment: Neutral

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients.

image for news Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

HOTH
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

Developed to address EGFR inhibitor-induced skin toxicities in cancer patients NEW YORK , June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 24, 2025, at 3:30PM EST. Access/join the event through the following link: https://zoom.us/j/91353016981.

image for news Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

HOTH
Published: June 18, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement. On June 18, 2025, the Company received formal notice from the Nasdaq Listing Qualifications Department confirming that Hoth's common stock closed at or above the $1.00 minimum bid price for 10 consecutive trading sessions—from June 4th through June 17- satisfying the requirement under Listing Rule 5550(a)(2).

image for news Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

HOTH
Published: June 12, 2025 by: PRNewsWire
Sentiment: Neutral

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK , June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No.

image for news Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

HOTH
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral

Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK , June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—such as rash and inflammation—often force patients to reduce or stop potentially life-saving cancer therapy.

image for news Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

HOTH
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral

HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity.

image for news Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

HOTH
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-KIT. The Company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ—genes implicated in allergic inflammation and mast cell-related diseases.

image for news Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

HOTH
Published: March 05, 2025 by: PRNewsWire
Sentiment: Neutral

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025 , highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.

image for news Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

About Hoth Therapeutics, Inc. (HOTH)

IPO Date 2019-02-15
Website https://www.hoththerapeutics.com
Industry Biotechnology
CEO Mr. Robb Knie
Employees 2

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.